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1) To fully explore the development of the novel, powerful cytotoxic compounds a strong 
collaboration among chemists, biochemists, pharmacologists and physicians is 
crucial.  
This thesis 
 
2) For the purposeful design of novel metal-based therapeutics, turning a designed 
compound into a drug-like molecule is a significant challenge, and in this process the 
design of compounds with well-defined absorption, distribution, metabolism and 
excretion mechanisms is crucial. 
This thesis 
 
3) The family of Au(III)-2-(arylazo)pyridine compounds are high-potential antitumour 
drugs due to their promising cytoxic activity; moreover, they  overcome cisplatin-
resistance. 
This thesis.  
 
4) When studying the biological activity of coordination compounds, the need of 
performing such tests also for the free ligands should be stressed. 
This thesis 
 
5) The Ru(III) bis(arylimino)pyridine compounds, which are easily chemical modified, are 
suitable starting materials for the synthesis of novel mononuclear Ru(II) species.  
This thesis 
 
6) The chemical structure of the most cytotoxic compound, RuL2, (trichlorido(2,6-
bis(2,6-diisopropylphenyliminomethyl)pyridine)ruthenium(III)), suggests that both 
steric and electronic factors could be determinant in the biological activity; these 
factors need to be further explored.  
This thesis. 
 
7) Capillar electrophoresis for the investigation of metallodrug metabolism, 
biotransformation and binding behaviour must be applied under physiological 
conditions in order to provide accurate information. 
J. Cuadrado, W. Zhang, W. Hang, V. Mahidi.J. Environ. Monit. 2 (2000) 355-359. 
Z. Huang, A. R. Timerbaev, B. K. Keppler, T. Hirokawa. J Chromatogr. A 1106 (2006) 
75-79. 
 
8) The epidemic of rising costs and blurred objectives that clinical trials are facing is 
discouraging in the testing of new medical treatments. 
See e.g. special issue Science 322 (2008).  
  
9) For optimal cancer care, treatment by multidisciplinary teams specialized in specific 
organ sites are extremely important.  
See e.g. M.H. N. Tattersall, H. Thomas. BMJ. 318 (1999) 445–448.  
 
10) Cancer prevention should become an integral part of worldwide cancer control.  
See e.g. S.-Y. Sun, N. Hail Jr., R. Lotan. J. Nat. Cancer Institute.  96 ( 2004) 662-672. 
 
11) When using cell lines in biological studies, one should be aware of the fact that, 
cross-contamination or misidentification of cell lines is a high risk.  
See e.g. I. R. I. Freshney, editorial. 2008. Expert. Rev. Anticancer. Ther. 8(3) 311-
314.  
 
12) In scientific research, it is often forgotten that negative results may also be very 
important and that relevant discoveries may be behind it.   
 
13) Our health and that of our children depends on the health of the environment. We 
must continue to do everything we can to protect it; after 23 years not really big 
improvements have been achieved.  
Erick Chivian Nobel Prize Winner 1985 
 
14) Not enough people appreciate the fact that one of the most sublime experiences we 
can ever have is to wake up feeling healthy after we have been sick. 
See e.g. Rabbi Harold Kushner  
 
15) When pursuing a research project, choose the topic you really like, because from 
start to finish you will devote a substantial amount of your “free” time to this 
endeavour. 
W. P. Naylor, C. A. Munoz-Viveros. J. Contemp. Dent Pract. 6 (2005) 164-180. 
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